Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma.
During normal B-lymphocyte development once cells pass the pro-B stage the transcription factor LEF-1, a key component of the Wnt/beta-catenin pathway, is down regulated. However studies have shown that B-cell chronic lymphocytic leukaemia (CLL) lymphocytes, which have a mature B-cell phenotype, still express abundant LEF-1. This study demonstrates that although LEF-1 mRNA is universally, highly expressed in B-CLL, expression of this gene is much lower or absent in the majority of low-grade B-cell non-Hodgkin's lymphoma (NHL). This suggests that there exist key differences in the activity of the Wnt/beta-catenin pathway between low-grade B-cell malignancies.
Howe
Denise
D
Leukaemia Research Laboratory, Taunton & Somerset NHS Trust, Musgrove Park Hospital, Taunton, Somerset TA1 5DA, UK. denise.howe@tst.nhs.uk
Bromidge
Teresa
T
D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D015536:Down-Regulation; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D051821:Lymphoid Enhancer-Binding Factor 1 / Q000096:biosynthesis* / Q000235:genetics; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D015398:Signal Transduction; D051153:Wnt Proteins / Q000378:metabolism; D051176:beta Catenin / Q000378:metabolism
D051821:Lymphoid Enhancer-Binding Factor 1; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D051153:Wnt Proteins; D051176:beta Catenin